Master Alliance Provisions Guide (MAPGuide)

BMGF – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments

  • Liability | Representations & Warranties

11. Subject to the waivers, releases and licenses granted by GSK to CureVac under this letter agreement, CureVac confirms that it has and will retain sufficient rights and licenses under all intellectual property and intellectual property rights owned or controlled by CureVac either (a) on the Effective Date or (b) in the conduct of Projects funded by BMGF after the Effective Date, to satisfy the Global Access License and related requirements under the Global Access Agreement. Further, CureVac confirms that nothing in the CLA limits CureVac’s ability to perform its obligations in the BMGF Agreements except as otherwise provided in this agreement.